Sigma Receptor Ligands for Selective Therapeutic Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's Disease, ALS, cancer, substance abuse, and other conditions lack effectiveness, and existing sigma receptor ligands often lack subtype selectivity and general selectivity.
Innovation Solution
Development of specific compounds that can selectively interact with sigma 1 or sigma 2 receptors, offering potential therapeutic benefits for various diseases by modulating receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing sigma receptor ligands are used, then therapeutic effects may be achieved, but subtype selectivity and general selectivity are lacking
Solution Approach 1:
The patent segments the sigma receptor ligand market by developing compounds that specifically target sigma-1 receptors versus sigma-2 receptors. The chemical structures are designed with specific substituents (R1-R6 groups) that determine selective binding to one subtype over the other, thereby achieving receptor subtype selectivity while maintaining therapeutic effectiveness for different indications
Solution Approach 2:
The patent applies local quality by modifying specific positions on the core chemical structure (positions 1-6 with different R groups) to achieve selective binding properties. Each substituent position contributes differently to the overall selectivity profile, allowing optimization of both therapeutic effectiveness and subtype selectivity through localized structural modifications
2Adaptability or versatility
If current treatments are used, then existing therapeutic approaches are maintained, but effectiveness for Alzheimer's, ALS, cancer, and other conditions is insufficient
Solution Approach 1:
The patent develops sigma receptor ligands with universal therapeutic potential across multiple disease indications including Alzheimer's disease, ALS, cancer, substance abuse, anxiety, depression, and neuropathic pain. The core chemical structure with variable substituents provides a versatile platform that can be optimized for different therapeutic targets while maintaining a unified mechanism of action through sigma receptor modulation
Data Source
AI summary
Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, and neuropathic pain.